|
|
Volumn 101, Issue 1, 2008, Pages 127-
|
|
The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy [1]
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CISPLATIN;
EPIRUBICIN;
FAS ANTIGEN;
GENTAMICIN;
IFOSFAMIDE;
METHOTREXATE;
MULTIDRUG RESISTANCE PROTEIN 2;
MULTIDRUG RESISTANCE PROTEIN 5;
PROTEIN BAX;
PROTEIN BCL 2;
PROTEIN BCL XL;
SURVIVIN;
VINCA ALKALOID;
VINCRISTINE;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
GEMCITABINE;
APOPTOSIS;
BLADDER CANCER;
CANCER CELL;
CANCER CHEMOTHERAPY;
CANCER RESISTANCE;
CANCER SURGERY;
CANCER SURVIVAL;
CYSTECTOMY;
GENE EXPRESSION;
HIGH RISK PATIENT;
HUMAN;
INVASIVE CARCINOMA;
LETTER;
LUNG NON SMALL CELL CANCER;
PRIORITY JOURNAL;
TRANSURETHRAL RESECTION;
TREATMENT OUTCOME;
BLADDER TUMOR;
DRUG RESISTANCE;
INTRAVESICAL DRUG ADMINISTRATION;
MORTALITY;
MULTIMODALITY CANCER THERAPY;
NOTE;
ADMINISTRATION, INTRAVESICAL;
ANTINEOPLASTIC AGENTS;
COMBINED MODALITY THERAPY;
CYSTECTOMY;
DEOXYCYTIDINE;
DRUG RESISTANCE, NEOPLASM;
EPIRUBICIN;
HUMANS;
URINARY BLADDER NEOPLASMS;
|
|
EID: 36849017489
PISSN: 14644096
EISSN: 1464410X
Source Type: Journal
DOI: 10.1111/j.1464-410X.2007.07380_1.x Document Type: Letter |
|
Times cited : (4)
|
|
References (2)
|
